drugset / Trial / NCT06425198
Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the drug levels and safety of BMS-986278 in participants with mild, moderate, and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
Timeline
- Start
- 2024-06-10
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Admilparant | Small molecule | — | — |
Indications
No indication recorded.